Latest Content

Prescribing of antiviral medication for children at risk of severe influenza decreased in COVID-19 pandemic despite unchanged treatment guidelines.

This week review more highlights from IDWeek, and why one researcher is predicting a milder avian influenza season.

Richard Webby, PhD, says increased wild bird immunity is a major factor for this year’s prediction.

Muhammad Sohaib Asghar, MBBS, MD, discusses why CDI deaths are concentrated in White patients and inpatient/long-term care settings, why mortality peaked in 2006–2015, and how stewardship and recurrence prevention are driving the recent decline.

In his new position, Gareth Morgan, MS, MBA, provides insights on antibiotic development strategies he would like to see during his tenure.

Bird migration has started. Surveillance and early detection are key, especially as it relates to H5N1 and predicting this year's respiratory virus season.

Jill Blumenthal, MD, MAS, offers some insights on the results from a subset of Gilead’s phase 3 PURPOSE 2 study.

The XpertHCV test from Cepheid enables rapid, point-of-care detection of hepatitis C infection in under an hour—helping to expand access to care and reduces follow-up loss.

At IDWeek, Jean van Wyk, MBChB, MFPM, chief medical officer at ViiV Healthcare, discussed the 96-week results from the PASO DOBLE study and the preliminary long-acting injectable PrEP results from the CLARITY study.

George Sakoulas, MD, discusses how transitioning pneumonia patients from IV to oral therapy after 3 to 4 days of clinical stability supports effective 7-day treatment courses, while patients who are immunocompromised and those with Pseudomonas infections require individualized, extended management.

Sustained HIV/syphilis elimination of mother-to-child transmission (EMTCT) since 2019 and new hepatitis B validation reflect high antenatal screening, >95% HBV birth-dose coverage, and integrated maternal–child health services.

The 2025 report from the WHO Global Antibiotic Resistance Surveillance System (GLASS) calls for urgent action against increasing threat of AMR. This is part 2 of 2-part coverage of the WHO Global Antibiotic Resistance Surveillance System Report 2025.

The Global Antimicrobial Resistance and Use Surveillance System (GLASS) of the WHO finds antibiotic resistance and the particular threat of resistant Gram-negative bacteria disproportionately prevalent in low- and middle-income countries. Here is part 1 of 2-part coverage of the WHO Global Antibiotic Resistance Surveillance Report.